Industry Speaks
The go-to 3D bioprinter for biomedical researchers
The ultimate goal of most biomedical research is to figure out how cells and molecules communicate in order to produce human tissues and organs. Scientists hope that by combining their knowledge of health and disease, they will be able to identify the most effective targets against which medications can be discovered and tested. However, such knowledge cannot be obtained directly from humans, thus models are used.
Researchers have engineered 3D in-vitro systems that can not only mimic the cellular/tissue level micro-physiological environment but also allow a systematic analysis of the key factors responsible for disease progression, thanks to recent advancements in microfabrication and soft lithographic processes.
Over the next five years, the 3D bioprinting sector is forecast to develop at a compound annual growth rate of 21.91 percent, with a global market value expected to rise from USD 1 billion in 2022 to USD 4.2 billion in 2027.
Every year, over five lakh people in India require organ transplantation, according to the National Organ and Tissue Transplant Organization (NOTTO). Many patients die as a result of a dearth of available transplant donors. Every day, 17 people in the country die while waiting for an organ transplant. The number of transplants performed has increased as a result of organ donation drives held around the country, but it is still nowhere near enough to close the gap between demand and supply for transplantable organs. 3D-bioprinting, is one technology that has showed significant promise in bridging the gap between organ availability and demand.
HiMedia refers to it as cutting-edge biotechnology for tomorrow’s leaders. Our 3D-bioprinter MITOTM manufactured by Avay Biosciences is designed not only for large pharmaceutical companies, but also for research institutes and schools interested in tissue engineering. Customization is essential in the global 3D bioprinting ecosystem, particularly in India. Our 3D-bioprinter is designed to be completely customizable in order to meet the needs of the Indian research community.
MITO 3D bioprinter
MITO is a range of extrusion-based bioprinters, specifically intended to meet the needs of the tissue engineering community. This technology has the potential to revolutionize toxicity research and drug screening, as well as tissue and organ transplantation. Print your scaffold designs in petri dishes, multi-well plates, or even customized lab-on-a-chip devices with MITO.
Application
Tissue engineering. MITO can be used to study the replication of skin, lung, liver, and bone tissue by experimenting with a variety of lab-specific bio inks (biomaterials+cells). Conduct research on tissue-identical performance, which can then be used by pharmaceutical companies for 3D cell interaction and feedback in drug testing.
Regenerative medicine. MITO is being used to produce biomaterials-based scaffolds to be used as a medical device that could provide as a stop-gap remedy for severe trauma cases, particularly for skin and bone replacement. It also possesses the potential to be used for tissue reconstitution, suitable for partial organ transplantation. Use the customizability of 3D printing to cater to each individual’s needs, and swiftly iterate through materials and architectures to find what works in real life.
In-vitro preclinical models – Organ-on-a-chip. By combining cells with biocompatible materials known as bioinks and by their precise deposition into desired structures, this new technology can be used as a tool for developing a variety of biological constructs for a versatile range of applications, including microfluidic devices, such as organ-on-a-chip and organoids from patient-specific cells for high-throughput drug development and precision medicine. In addition, this technology can be used to develop more relevant study models for disease.
